These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 15867164)

  • 21. Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs.
    Sandercock P; Berge E; Dennis M; Forbes J; Hand P; Kwan J; Lewis S; Lindley R; Neilson A; Wardlaw J
    Stroke; 2004 Jun; 35(6):1490-7. PubMed ID: 15105519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment of acute ischemic apoplexy].
    Andersen G; Krieger DW; Iversen HK
    Ugeskr Laeger; 2009 Mar; 171(13):1094. PubMed ID: 19321089
    [No Abstract]   [Full Text] [Related]  

  • 23. Acute ischemic stroke.
    Chiti A; Giorli E; Orlandi G
    N Engl J Med; 2007 Nov; 357(21):2203; author reply 2204. PubMed ID: 18032775
    [No Abstract]   [Full Text] [Related]  

  • 24. Expediting MRI-based proof-of-concept stroke trials using an earlier imaging end point.
    Ebinger M; Christensen S; De Silva DA; Parsons MW; Levi CR; Butcher KS; Bladin CF; Barber PA; Donnan GA; Davis SM;
    Stroke; 2009 Apr; 40(4):1353-8. PubMed ID: 19246703
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Should thrombolytic therapy be the first-line treatment for acute ischemic stroke?
    Schneck MJ
    N Engl J Med; 1998 Mar; 338(11):762; author reply 762-3. PubMed ID: 9499173
    [No Abstract]   [Full Text] [Related]  

  • 26. Response to letter regarding article, "Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion".
    Coutts SB; Hill MD
    Stroke; 2015 Jun; 46(6):e150. PubMed ID: 25899240
    [No Abstract]   [Full Text] [Related]  

  • 27. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: way to endeavor.
    Huang P; Chen CH; Yang YH; Lin RT; Lin FC; Liu CK
    Cerebrovasc Dis; 2006; 22(5-6):423-8. PubMed ID: 16912476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Challenges in management of ischemic stroke secondary to brachiocephalic artery dissection.
    Sansone T; Baroncelli S; Tozzetti C; Berni A; Torri M
    Intern Emerg Med; 2013 Mar; 8(2):181-3. PubMed ID: 23054410
    [No Abstract]   [Full Text] [Related]  

  • 29. Editorial comment--Remote evaluation of acute ischemic stroke: a reliable tool to extend tissue plasminogen activator use to community and rural stroke patients?
    Crome O; Bähr M
    Stroke; 2003 Oct; 34(10):e191-2. PubMed ID: 14500919
    [No Abstract]   [Full Text] [Related]  

  • 30. Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke: real-world experience and a call for action.
    Bhatia R; Hill MD; Shobha N; Menon B; Bal S; Kochar P; Watson T; Goyal M; Demchuk AM
    Stroke; 2010 Oct; 41(10):2254-8. PubMed ID: 20829513
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The smoking-thrombolysis paradox and acute ischemic stroke.
    Fisher M
    Neurology; 2006 Feb; 66(3):458; author reply 458. PubMed ID: 16476964
    [No Abstract]   [Full Text] [Related]  

  • 32. Tenecteplase versus alteplase for acute ischemic stroke.
    González RG
    N Engl J Med; 2012 Jul; 367(3):275-6; author reply 276. PubMed ID: 22808969
    [No Abstract]   [Full Text] [Related]  

  • 33. Will symptomatic intracerebral hemorrhages decrease among eligible dabigatran-treated patients who receive intravenous tissue plasminogen activator for acute ischemic stroke?
    Chan L
    Arch Neurol; 2010 Sep; 67(9):1156; author reply 1156-7. PubMed ID: 20837869
    [No Abstract]   [Full Text] [Related]  

  • 34. The use of intravenous recombinant tissue plasminogen activator in acute ischemic stroke.
    Kahn JH; Viereck J; Kase C; Jeerakathil T; Romero R; Mehta SD; Kociol R; Babikian V
    J Emerg Med; 2005 Oct; 29(3):273-7. PubMed ID: 16183445
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The hard way to acute stroke treatment.
    Sironi L; Gelosa P; Tremoli E; Cimino M
    J Hypertens; 2008 Dec; 26(12):2274-5. PubMed ID: 19008704
    [No Abstract]   [Full Text] [Related]  

  • 36. Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke.
    Krams M; Lees KR; Hacke W; Grieve AP; Orgogozo JM; Ford GA;
    Stroke; 2003 Nov; 34(11):2543-8. PubMed ID: 14563972
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Non-contrast brain ct based systemic thrombolysis of two wake up ischemic stroke patients in rural settings].
    Pozsegovits K; Rencz L; Csúsz L; Szabó G
    Ideggyogy Sz; 2017 May; 70(5-6):209-212. PubMed ID: 29870636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reasons for exclusion from thrombolytic therapy following acute ischemic stroke.
    Kleindorfer DO; Khatri P; Katzan I
    Neurology; 2005 Dec; 65(11):1844; author reply 1844. PubMed ID: 16353320
    [No Abstract]   [Full Text] [Related]  

  • 39. Letter by Behrouz et Al regarding article, "Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion".
    Behrouz R; Mutgi SA; Silver B
    Stroke; 2015 Jun; 46(6):e149. PubMed ID: 25899241
    [No Abstract]   [Full Text] [Related]  

  • 40. Intraarterial recombinant tissue plasminogen activator for ischemic stroke: an accelerating dosing regimen.
    Qureshi AI; Suri MF; Shatla AA; Ringer AJ; Fessler RD; Ali Z; Guterman LR; Hopkins LN
    Neurosurgery; 2000 Aug; 47(2):473-6; discussion 477-9. PubMed ID: 10942026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.